Damora Therapeutics (DMRA) Free Cash Flow (2019 - 2026)

Damora Therapeutics has reported Free Cash Flow for 8 years, with the latest figure at -$20.6 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 758.33% year-over-year to -$20.6 million; the trailing twelve-month figure through Mar 2026 stood at -$24.9 million (down 65.07% YoY), and the FY2025 full-year result was -$6.7 million, up 63.84% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$20.6 million, down from $574000.0 in the prior quarter.
• The five-year high for Free Cash Flow was $574000.0 in Q4 2025, with the low at -$20.6 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$7.4 million across 5 years, with a median of -$6.8 million in 2022.
• Annual changes were most pronounced in 2025 — Free Cash Flow surged 111.68% — and 2026, when it tumbled 758.33%.
• Damora Therapeutics' Free Cash Flow stood at -$11.5 million in 2022, then grew by 0.23% to -$11.5 million in 2023, then jumped by 57.14% to -$4.9 million in 2024, then surged by 111.68% to $574000.0 in 2025, then slumped by 3688.85% to -$20.6 million in 2026.
• The last three Free Cash Flow figures came in at -$20.6 million (Q1 2026), $574000.0 (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.